Literature DB >> 16014749

Siglecs--the major subfamily of I-type lectins.

Ajit Varki1, Takashi Angata.   

Abstract

Animal glycan-recognizing proteins can be broadly classified into two groups-lectins (which typically contain an evolutionarily conserved carbohydrate-recognition domain [CRD]) and sulfated glycosaminoglycan (SGAG)-binding proteins (which appear to have evolved by convergent evolution). Proteins other than antibodies and T-cell receptors that mediate glycan recognition via immunoglobulin (Ig)-like domains are called "I-type lectins." The major homologous subfamily of I-type lectins with sialic acid (Sia)-binding properties and characteristic amino-terminal structural features are called the "Siglecs" (Sia-recognizing Ig-superfamily lectins). The Siglecs can be divided into two groups: an evolutionarily conserved subgroup (Siglecs-1, -2, and -4) and a CD33/Siglec-3-related subgroup (Siglecs-3 and -5-13 in primates), which appear to be rapidly evolving. This article provides an overview of historical and current information about the Siglecs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014749     DOI: 10.1093/glycob/cwj008

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  208 in total

1.  Specific inactivation of two immunomodulatory SIGLEC genes during human evolution.

Authors:  Xiaoxia Wang; Nivedita Mitra; Ismael Secundino; Kalyan Banda; Pedro Cruz; Vered Padler-Karavani; Andrea Verhagen; Chris Reid; Martina Lari; Ermanno Rizzi; Carlotta Balsamo; Giorgio Corti; Gianluca De Bellis; Laura Longo; William Beggs; David Caramelli; Sarah A Tishkoff; Toshiyuki Hayakawa; Eric D Green; James C Mullikin; Victor Nizet; Jack Bui; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression.

Authors:  Sherry A Hudson; Harald Herrmann; Jian Du; Paul Cox; El-Bdaoui Haddad; Barbara Butler; Paul R Crocker; Steven J Ackerman; Peter Valent; Bruce S Bochner
Journal:  J Clin Immunol       Date:  2011-09-22       Impact factor: 8.317

3.  IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils.

Authors:  Ho Jeong Na; Sherry A Hudson; Bruce S Bochner
Journal:  Cytokine       Date:  2011-11-12       Impact factor: 3.861

Review 4.  Regulation of microglial activation in stroke.

Authors:  Shou-Cai Zhao; Ling-Song Ma; Zhao-Hu Chu; Heng Xu; Wen-Qian Wu; Fudong Liu
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

Review 5.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

6.  Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8.

Authors:  Ho Jeong Na; Robert G Hamilton; Amy D Klion; Bruce S Bochner
Journal:  J Immunol Methods       Date:  2012-06-06       Impact factor: 2.303

7.  Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography.

Authors:  Weiqian Cao; Jing Cao; Jiangming Huang; Lei Zhang; Jun Yao; Haoqi Xu; Pengyuan Yang
Journal:  Glycoconj J       Date:  2012-07-08       Impact factor: 2.916

Review 8.  Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.

Authors:  B S Bochner
Journal:  Clin Exp Allergy       Date:  2009-03       Impact factor: 5.018

9.  Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.

Authors:  Whitney W Stevens; Taeg S Kim; Lindsey M Pujanauski; Xueli Hao; Thomas J Braciale
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

Review 10.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.